"Furthermore, in January, Cynata secured $6 million in a Placement of 9.23 million shares at $0.65c to sophisticated and institutional investors. The funds raised during the quarter have resulted in the Company closing the quarter with $11.6 million cash at bank. The funds will be used to continue to develop its the Cymerus therapeutic MSC products in its key target areas of GvHD, cardiovascular disease, oncology (glioblastoma) and respiratory disease. Based on current plans this cash position should provide the Company with a runway beyond 2018."
CYP Price at posting:
42.0¢ Sentiment: Buy Disclosure: Held
